171 related articles for article (PubMed ID: 29032291)
1. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Martínez P; Galve E; Arrazubi V; Sala MÁ; Fernández S; Pérez CE; Arango JF; Torre I
Reumatol Clin (Engl Ed); 2019; 15(4):211-217. PubMed ID: 29032291
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
3. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
5. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
7. Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
J Bone Miner Res; 2019 Aug; 34(8):1428-1435. PubMed ID: 31069862
[TBL] [Abstract][Full Text] [Related]
8. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer and osteoporosis.
Cheung AM; Heisey R; Srighanthan J
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
[TBL] [Abstract][Full Text] [Related]
10. Bone-Targeted Therapy in Early Breast Cancer.
Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
[TBL] [Abstract][Full Text] [Related]
11. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
13. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
14. [Treatment effect of breast cancer and prostate cancer on bone].
Varsavsky M; Guadalix Iglesias S
Med Clin (Barc); 2013 Feb; 140(4):164-8. PubMed ID: 22841464
[TBL] [Abstract][Full Text] [Related]
15. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
17. Screening for osteoporosis after breast cancer: for whom, why and when.
Trémollieres FA
Maturitas; 2014 Nov; 79(3):343-8. PubMed ID: 25308162
[TBL] [Abstract][Full Text] [Related]
18. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
19. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
Bailey S; Mhango G; Lin JJ
Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
[TBL] [Abstract][Full Text] [Related]
20. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]